B cell receptor signaling in chronic lymphocytic leukemia.
about
TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsSecondary mutations as mediators of resistance to targeted therapy in leukemiaCD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humansProteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development.Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaTCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signalingRewiring of sIgM-mediated intracellular signaling through the CD180 Toll-like receptor.Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemiaTreatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.Ibrutinib: a paradigm shift in management of CLL.Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.Chronic lymphocytic leukemia therapy: new targeted therapies on the wayAssessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia.Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Shifting paradigms in the treatment of chronic lymphocytic leukemia.A systematic approach for peptide characterization of B-cell receptor in chronic lymphocytic leukemia cells.Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Twist as a new prognostic marker in hematological malignancies.
P2860
Q26773053-5943421E-0A96-442E-BC6D-3893B0C1C7B3Q26775506-B9F71CA4-0BBA-4495-9ED6-3D177B9AE0E6Q26782633-2BB9D5E7-8710-471E-9C52-FCC2E191B6D8Q26798062-F0B79DD8-4129-4461-A4B3-761D5B0780CDQ28081162-4DD8CB85-DD7C-4F77-8E1B-AB60F2715274Q28087213-1F7217D4-CCD1-48EC-9A61-4AF47265A2FCQ28543785-EC61B83C-6566-4E32-9B15-9AEDA948124FQ28545914-E90E4D40-F3BA-47E8-B8C7-43F40BA6D846Q30248557-CDCA3C34-A5E3-4C4F-A106-4CD61A4920F6Q30252869-85CF4FEA-4A7D-4D46-B548-05A00255897EQ30303054-95416D22-5B65-4DE8-A2B1-A7CA3DC4B3C9Q33598691-C17B24A1-32C1-4B88-9211-0923A8010574Q33798525-DEC8E33E-3AA4-4167-B58B-1BA68286BA3AQ33920352-7166D6B7-106F-43EB-BBE5-8981C0DF4DCAQ34009064-71FB608A-A270-4818-AE8D-A8343D37FCDDQ34280885-73D4A8E5-2B8D-400E-B7EE-D724D9B1B132Q34419383-0E9CC4BB-A394-417E-95BA-21BA0EFAD9D6Q34534572-506E821C-5B64-41EE-9F1D-28BFEC6AB717Q35128888-27445A88-84F2-420B-A8D0-C92C922CDCE5Q35634885-5EE13274-4131-4FB2-9D55-F6AB5F5B27F0Q35707093-13645267-0322-4DE5-AA67-4B5B6EC28597Q35775881-7710C019-7D4F-4E92-A628-6BBF7B50D709Q35861964-B059E242-9887-44DD-94DA-185035D4566DQ35941236-9409BABA-FE79-4D74-9A8E-DA655C2AD6C1Q36172601-BE0F7497-8732-4FC1-BF48-84EED86DDF46Q36437030-3368BD1F-D3D9-4361-93F8-CA211AD896C1Q36519986-9F9A417F-EE66-4080-AEDB-DA7E631CD6C4Q36544769-450BF21A-A8B4-4113-A00F-5D73B6D6B752Q36739295-3F0FE54E-B373-49EF-9D49-5F46B868680AQ36925503-F91B5498-8AB2-4A61-A889-C7824C6B2C9CQ37113544-8886F514-1CC2-494A-B4BC-7A18C4142E4AQ37362785-4200FB2A-F943-4D39-826D-20EF5763C38EQ37599562-DFCEB93D-D08B-4530-AEB1-E74E502701DAQ38205852-0D8BB5E7-D019-42CA-A8C0-5E766D569835Q38340201-82222E46-EBD2-40E7-8AF7-688A348F57CAQ38357127-A0BF4FFD-B62B-4904-9907-D877C22A52E3Q38377249-E8F6F71D-ED96-4773-B007-92E9E3813D99Q38413580-FA25D783-B3E9-473D-BF37-A121EC179036Q38550810-8A4514CB-90A2-4CB2-9446-802BC5DDA92EQ38552664-3AA6DB20-F652-48B2-AF2C-B7B5AFB4F9F9
P2860
B cell receptor signaling in chronic lymphocytic leukemia.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
B cell receptor signaling in chronic lymphocytic leukemia.
@en
type
label
B cell receptor signaling in chronic lymphocytic leukemia.
@en
prefLabel
B cell receptor signaling in chronic lymphocytic leukemia.
@en
P2860
P356
P1433
P1476
B cell receptor signaling in chronic lymphocytic leukemia.
@en
P2093
Jan A Burger
Nicholas Chiorazzi
P2860
P304
P356
10.1016/J.IT.2013.07.002
P577
2013-08-05T00:00:00Z